Research and Clinical Trials
We play an active and leading role in cancer research through partnerships with Sarah Cannon Research Institute, Alliance for Clinical Trials in Oncology, and various pharmaceutical companies. These studies help to find better ways to treat cancer and give patients, who are eligible to participate, access to new investigational therapies that are otherwise not yet generally available. Every cancer is different for each patient, and so is our approach to treatment. Our clinical research team evaluates the latest advances and treatments that meet the patient’s individual needs.
What Happens during a Clinical Trial?
What is informed consent?
Why are Clinical Trials important?
Should I participate in a Clinical Trial?
Why Do Some Cancer Patients Choose to Participate in Clinical Trials?
How are Clinical Trials Structured?
- In Phase I clinical trials, researchers test a study drug in a small group of people (20 to 80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
- In Phase II clinical trials, the study drug is tested in a larger group of people (100 to 300) to measure its effectiveness and further evaluate its safety.
- In Phase III clinical trials, the study drug is tested in larger groups of people (1,000 to 3,000) to confirm its effectiveness, monitor side effects, compare it to approved standard treatments, and collect information that will allow the study drug to be used safely.
- In Phase IV clinical trials, the drug is tested after it has been marketed to collect information about its effect in various populations and about any side effects associated with long-term use.